NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

Context Therapeutics logo
$0.16 -0.01 (-4.51%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$0.16 0.00 (-0.62%)
As of 11/20/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Context Therapeutics Stock (NASDAQ:CNTX)

Advanced

Key Stats

Today's Range
$0.16
▼
$0.18
50-Day Range
$0.16
▼
$0.39
52-Week Range
$0.15
▼
$3.62
Volume
1.11 million shs
Average Volume
1.61 million shs
Market Capitalization
$14.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.40
Consensus Rating
Moderate Buy

Company Overview

Context Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells.

Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors.

Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.

AI Generated. May Contain Errors.

Context Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

CNTX MarketRank™: 
1.99285013318 of 5 stars

Context Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 623rd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Context Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Context Therapeutics has a consensus price target of $6.40, representing about 3,875.2% upside from its current price of $0.16.

  • Amount of Analyst Coverage

    Context Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Context Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.44) to ($0.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Context Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Context Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Context Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.37% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 3.68, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Context Therapeutics has recently increased by 9.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Context Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Context Therapeutics does not have a long track record of dividend growth.

  • Search Interest

    Only 1 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.80% of the stock of Context Therapeutics is held by insiders.

  • Percentage Held by Institutions

    14.03% of the stock of Context Therapeutics is held by institutions.

  • Read more about Context Therapeutics' insider trading history.
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNTX Stock News Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Headlines

CNTX Stock Analysis - Frequently Asked Questions

Context Therapeutics' stock was trading at $1.47 on January 1st, 2026. Since then, CNTX stock has decreased by 89.0% and is now trading at $0.1610.

Context Therapeutics Inc. (NASDAQ:CNTX) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03.

Context Therapeutics (CNTX) raised $25 million in an IPO on Tuesday, October 19th 2021. The company issued 5,000,000 shares at $5.00 per share.

Top institutional investors of Context Therapeutics include State Street Corp (1.58%), Russell Investments Group Ltd. (0.73%), Goldman Sachs Group Inc. (0.45%) and Landscape Capital Management L.L.C. (0.26%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit.
View institutional ownership trends
.

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
11/10/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CNTX
CIK
1842952
Fax
N/A
Employees
15
Year Founded
2015

Price Target and Rating

High Price Target
$9.00
Low Price Target
$4.00
Potential Upside/Downside
+3,875.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.12 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-96.54%
Return on Assets
-83.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.59
Quick Ratio
6.59

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.34 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
91,879,000
Free Float
87,469,000
Market Cap
$14.79 million
Optionable
Not Optionable
Beta
1.77

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:CNTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners